Aarti Drugs is fundamentally a maker of the active molecules that go into medicines - the chemical heart of a pill - built over four decades inside the Aarti Group, a chemicals conglomerate. It began in 1984, absorbed seven allied chemical companies in 1996, and later pushed forward from bulk drugs into finished-dose formulations in 2014, creating a recurring pattern: master a high-volume chemistry, then integrate backwards to own the raw materials that rivals have to buy. That approach - scale a molecule, then climb up its supply chain - explains almost every plant, partnership and product line the company has added since.
Business segments
Two engines, one feeding the other - a bulk-drugs cash cow built on backward integration and global scale, and a younger formulations business that turns those same molecules into finished pills for export markets.
1. Active Pharmaceutical Ingredients: the molecule factory
The company makes over 50 bulk drug molecules at industrial scale, is the world’s largest producer of several of them, and keeps winning despite falling prices because it owns more of its raw-material chain than competitors do.
- Backward integration is the cost moat - for 14-15 products that together bring in 88-90% of sales, the company makes its own key intermediates rather than buying them, and it is the only backward integrated player in the Indian market for fluoroquinolone antibiotics and is backward integrated for its anti-fungal line.
- Scale that few can match - total installed capacity reached 82,512 tonnes per year in FY26, housed across up to 14 plants with reactor vessels ranging from half a kilolitre to 18 kilolitres, giving it the ability to run everything from small development batches to multi-tonne commercial campaigns.
- A deliberate shift into premium chemistry - after years of price declines (pricing fell 18% in FY24 and 13% in FY25), the company is tilting its mix toward specialized molecules that carry higher margins, including a dedicated site for oncology drugs coming off patent and a new skincare therapy entering the API portfolio.
- The methylamine bet closes a raw-material gap - a new plant at Sayakha, Gujarat, started making methylamines in September 2025 and was already producing nearly 1,000 tonnes a month by March 2026, reducing dependence on outside suppliers for the metformin anti-diabetic chain, where the company runs over 1,450 tonnes of monthly capacity.
- Regulatory wins reopen rich markets - the Tarapur API plant was cleared from a USFDA import alert in February 2025, allowing exports to the US of specific molecules including ciprofloxacin hydrochloride and Celecoxib, which widens the addressable customer base in the world’s largest drug market.
2. Formulations: the pill-making downstream bet
A wholly owned subsidiary turns the group’s own APIs into finished tablets and capsules, then licenses them to local distributors abroad - so it earns a margin on the molecule and a second margin on the dose.
- Built on the parent’s chemistry, sold through partners - the formulations business develops its own products and dossiers, holds the intellectual property, and out-licenses them to local marketing partners in international markets, while domestic sales are mostly contract manufacturing for other pharma companies.
- Exports are the growth engine - 65% of the segment’s revenue came from outside India in FY26, with commercial operations now live in Latin America and parts of Africa, supported by roughly 330 regulatory filings across 16 countries.
- A plant built for regulated markets - the Baddi facility in Himachal Pradesh carries UKMHRA, WHO-GMP and USFDA approvals, with installed capacity of 3 billion tablets and 300 million capsules, and a separate USFDA-approved oncology formulation line.
- Pipeline follows the patent cliff - products under development include anti-coagulants and anti-diabetics for regulated markets, plus a range of anti-infectives and cardiovascular drugs for Latin America and emerging markets, aiming for day-one launches when originator patents expire.
Group structure and partners
Aarti Drugs operates through a parent company with three active subsidiaries - one making pills, one making specialty chemicals, and one opening a distribution front in Latin America - plus a joint venture and a captive solar investment that together lower its technology and energy costs.
- Pinnacle Life Science Private Limited is the wholly owned formulations subsidiary, based in Baddi, and is the vehicle for the entire finished-dosage business.
- Aarti Speciality Chemicals Limited is a wholly owned subsidiary that won a government PLI-scheme approval for 2-Methyl-5Nitro-Imidazole, committing to 4,000 tonnes per year of capacity and roughly ₹78 crores of investment.
- Pinnacle Chile SpA and its step-down subsidiaries (Pharma Go SpA and Tripharma Chile SpA) were set up in Santiago to market formulation drugs and participate in public tenders and private contracts across the region.
- A Chinese joint venture supplies technology for the anti-protozoal product line, while a European distributor tie-up operates on a profit-sharing model for finished formulations in the UK, and a US partner buys API at cost for a shared formulation venture.